ClinicalTrials.gg
CompletedNCT01075100Updated Dec 7, 2016Results posted

Ixabepilone + Carboplatin Metastatic Breast Cancer

A Phase 2 interventional study of Ixabepilone and Carboplatin in Metastatic Breast Cancer, sponsored by US Oncology Research. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-07.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.

Enrollment
13th of 39
103 · median 56
Started
2010
with 1 other
Phase 2
24 of 41
none open now
Registered
36th of 41
by date

Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2010, is one of 24 in phase 2, and was the 36th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About ixabepilone

ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing ixabepilone in Breast Neoplasms as a file.
02

Study summary

Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A Phase I study of ixabepilone plus carboplatin in solid tumor patients demonstrated the safety of this combination at the doses and schedule proposed for this Phase II trial (BMS data on file).

Read the detailed description

This is a Phase II, open label, nonrandomized, parallel, noncomparative, study of 2 groups (as stratified below). All patients will receive ixabepilone 20 mg/m2 on Days 1 and 8 and carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle. Patients will be stratified by either hormone receptor positive [ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-]- (n=50) or triples negative ER-/PR-/HER2- (n=53). If one group fulfills their accrual goal first, registration into that strata will be stopped and only patients meeting stratification requirements for the other group will be registered.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • metastatic
  • breast
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female patients will be eligible for inclusion in this study if they meet all of the following criteria:

  1. Has measurable and or locally unresectable breast cancer with documented negative (-) disease
  2. Has at least 1 per criteria (lesions that can be accurately measured in at least 1 dimension (longest diameter (LD) to be recorded) as ≥20 mm with conventional techniques (CT, MRI, X-ray) or as ≥10 mm with spiral CT scan). Irradiated lesions cannot be used to assess response but can be used to assess progression.
  3. Has received up to 2 (0 to 2) prior chemotherapy regimens for metastatic disease with the following conditions:

    •Has had no prior treatment with ixabepilone or platinum agents

  4. Has had no chemotherapy within the 6 months prior to study, but may have received prior anthracyclines and/or taxanes as adjuvant chemotherapy
  5. 3 weeks or more have elapsed since last chemotherapy treatment and any related toxicities have resolved to \<Grade 1; at least 30 days must have passed since any product has been administered and associated toxicities must have resolved to \<Grade 1 (if applicable).
  6. Has an Performance Status (PS) 0-2
  7. Is ≥18 years of age
  8. Has a of at least 12 weeks
  9. Has laboratory values of:

    White blood cell (WBC) count ≥3000 x 106/L (ANC) ≥1500 x 106/L ≥9 g/dL Total ≤1x (ULN) and ALT ≤2.5 x ULN Alkaline phosphatase ≤2.5 x ULN; up to 5xULN if elevation is due to bone disease Serum creatinine ≤1.5 mg/dL Calculated >50 mL/min (based on Cockroft and Gault method [Appendix III]) count ≥100,000 x 106/L

  10. If patient has had radiation therapy, it has been completed >3 weeks prior to the start of study treatment. NOTE: Previously irradiated lesions will not be evaluable. However, these patients will still be eligible.
  11. Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of [not surgically sterilized and between menarche and 1 year
  12. If fertile, patient (male or female) has agreed to use an acceptable method of to avoid pregnancy for the duration of the study and for a period of 3 months thereafter
  13. Has signed the most recent Patient Form
  14. Has signed a Patient Authorization Form Note: Having tissue available is not an inclusion criterion in this study; however, available tissue will be collected (see Section 8) if possible.

Exclusion criteria

Exclusion Criteria:

A patient will be excluded from this study if he or she meets any of the following criteria:

  1. Had prior treatment with ixabepilone or other epothilones
  2. Had prior radiation to ≥30% of major bone marrow containing areas (pelvis, lumbar spine)
  3. Has ER+ and/or PR+ disease that has not progressed on hormone therapy, unless the patient has life-threatening or rapidly progressing visceral disease
  4. Has + disease (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive tumor cells]), a FISH result of more than 6 HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals of >2.2)
  5. Has only lytic bone disease or nonmeasurable disease only
  6. Has a known, prior, severe ( Grade 3-4) history of reaction to a drug formulated in Cremophor®EL (polyoxyethylated castor oil) or has history of severe allergic reactions to cisplatin or other platinum-containing compounds
  7. Has been treated previously with a platinum-containing agent
  8. Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. for these prior therapies are specified in Section 5.
  9. Is receiving concurrent therapy or has received such therapy within the 30 days prior to dosing Day 1
  10. Has neuropathy (motor or sensory) >Grade 1
  11. Has evidence of CNS involvement requiring radiation or treatment. Patients with stable who are off steroids at least 2 weeks are eligible.
  12. Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  13. Has coagulopathy either secondary to hepatic dysfunction or an underlying condition requiring therapeutic anticoagulation (specifically, A-fib, history of DVT). A daily aspirin or Plavix for CAD are permitted.
  14. Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs
  15. Is a pregnant or breast feeding woman
  16. Is unable to comply with the requirements of the study
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Weekly Ixabepilone +carboplatin

    Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.

    Drug: Ixabepilone · Drug: Carboplatin

Interventions

  • 20 mg/m2 on Days 1 and 8

    Also known as: Ixempra, azaepothilone B

  • carboplatin AUC=2.5 on Days 1 and 8

    Also known as: Paraplatin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Evaluate the objective response rate calculated as CR+ PR in the population evaluable for response, as well as the 2 subgroups (hormone receptor positive \[ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-\]) and ER-/PR-HER2-, separately). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 24 months

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    Clinical benefit rate (CBR) defined as objective response rate (ORR, CR + PR) + SD \>= 6 months

    Time frame: 24 months

  2. Progression-free Survival (PFS)

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: 24 months

  3. Overall Survival (OS)

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 24 months

  4. Time to Response

    For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

    Time frame: 24 months

  5. Duration of Response

    The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

    Time frame: 30 months

07

Results

Posted Dec 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneTriple NegativeHR Positive
Started4954
Completed01
Not completed4953
Withdrew: Adverse event1518
Withdrew: Patient request44
Withdrew: Investigator request21
Withdrew: Disease progression2529
Withdrew: Other31

Outcome measures

PrimaryObjective Response Rate (ORR)

Evaluate the objective response rate calculated as CR+ PR in the population evaluable for response, as well as the 2 subgroups (hormone receptor positive \[ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-\]) and ER-/PR-HER2-, separately). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
24 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTriple NegativeHR Positive
Objective Response Rate (ORR)30.4 (17.7 to 45.8)34 (21.5 to 48.3)
SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate (CBR) defined as objective response rate (ORR, CR + PR) + SD \>= 6 months

Time frame:
24 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsTriple NegativeHR Positive
Clinical Benefit Rate (CBR)41.3 (27.0 to 56.8)56.6 (42.3 to 70.2)
SecondaryProgression-free Survival (PFS)

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
24 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTriple NegativeHR Positive
Progression-free Survival (PFS)7.6 (4.3 to 8.4)7.6 (4.2 to 9.8)
SecondaryOverall Survival (OS)

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
24 months
Reported as:
Median · months
Overall Survival (OS)
monthsTriple NegativeHR Positive
Overall Survival (OS)12.5 (10.2 to 14.2)17.9 (14.4 to 22.4)
SecondaryTime to Response

For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

Time frame:
24 months
Reported as:
Median · months
Time to Response
monthsTriple NegativeHR Positive
Time to Response1.27 (0.92 to 3.98)1.60 (1.12 to 8.95)
SecondaryDuration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

Time frame:
30 months
Reported as:
Median · months
Duration of Response
monthsTriple NegativeHR Positive
Duration of Response6.68 (2.43 to 20.4)5.92 (1.84 to 25.6)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple Negative—10/48 (20.8%)44/48 (91.7%)
HR Positive—5/53 (9.4%)52/53 (98.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventTriple NegativeHR Positive
DEHYDRATIONGastrointestinal disorders4/480/53
DIARRHEAGastrointestinal disorders4/480/53
NAUSEAGastrointestinal disorders3/481/53
VOMITINGGastrointestinal disorders2/481/53
ABDOMINAL PAINGastrointestinal disorders1/480/53
DIZZINESSNervous system disorders1/480/53
FEVERGeneral disorders1/481/53
FIBRILLATION ATRIALCardiac disorders1/480/53
HYPOKALEMIAMetabolism and nutrition disorders1/480/53
HYPONATREMIAMetabolism and nutrition disorders1/480/53
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTriple NegativeHR Positive
NEUTROPENIABlood and lymphatic system disorders31/4839/53
FATIGUEGeneral disorders18/4831/53
NAUSEAGastrointestinal disorders23/4831/53
ANEMIABlood and lymphatic system disorders27/4828/53
NEUROPATHYNervous system disorders22/4827/53
THROMBOCYTOPENIABlood and lymphatic system disorders16/4825/53
ALOPECIASkin and subcutaneous tissue disorders15/4820/53
VOMITINGGastrointestinal disorders8/4819/53
DIARRHEAGastrointestinal disorders13/4815/53
LEUCOPENIABlood and lymphatic system disorders6/4814/53

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Triple NegativeHR PositiveTotal
Mean55.0 ± 9.056.7 ± 10.655.9 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Triple NegativeHR PositiveTotal
Female4954103
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Triple NegativeHR PositiveTotal
Caucasian333972
Hispanic224
Hawaiian011
Black141024
Asian022
Region of Enrollment
Region of Enrollment(participants)Triple NegativeHR PositiveTotal
United States4954103
08

Study locations

59 sites
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Arizona Oncology Associates, PC - NAHOA
    Sedona, Arizona 86336, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Southwest Cancer care
    Murrieta, California 92562, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80220, United States
  • Florida Cancer Institute - New Hope
    Hudson, Florida 34667, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Florida Institute of Research, Medicine & Surgery
    Ocoee, Florida 34761, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Carmel, Indiana 46032, United States
  • Alliance Hematology Oncology, P.A.
    Westminster, Maryland 21157, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Maryland Oncology Hematology, PA The Medical Pavillion at Howard County
    Columbia, Missouri 21044, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Kansas City Cancer Center, LLC
    Kansas City, Missouri 64131, United States
  • St. Joseph Oncology, Inc.
    St. Joseph, Missouri 64507, United States
  • Comprehensive Cancer Care Centers of Nevada
    Henderson, Nevada 89074, United States
  • Hematology-Oncology Associates of Northern NJ, PA Carol G. Simon Cancer Center
    Morristown, New Jersey 07962, United States
  • Ruth Oratz MD
    New York, New York 10016, United States
  • Interlakes Oncology & Hematology, P.C
    Rochester, New York 14623, United States
  • Raleigh Hematology Oncology Associates
    Raleigh, North Carolina 27607, United States
  • Dayton Oncology & Hematology, P.A. Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Northwest Cancer Specialists, PC
    Portland, Oregon 97213, United States
  • Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Texas Oncology - Abilene
    Abilene, Texas 79606, United States
  • Texas Oncology - Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology - Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology Medical City Dallas
    Dallas, Texas 75230, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology-Methodist Charlton Cancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • Texas Oncology- Denton South
    Denton, Texas 76210, United States
  • Texas Oncology-Fort Worth 12 Ave
    Fort Worth, Texas 76104, United States
  • Texas Oncology-Memorial City
    Houston, Texas 77024, United States
  • Texas Oncology- Lewisville
    Lewisville, Texas 75067, United States
  • Texas Oncology-Longview Cancer Center
    Longview, Texas 75601, United States
  • Texas Oncology-McAllen South Second Street
    McAllen, Texas 78509, United States
  • Texas Oncology-Mesquite
    Mesquite, Texas 75150, United States
  • Texas Oncology-Midland Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology- Odessa West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78217, United States
  • Cancer Care Centers of South Texas-HOAST
    San Antonio, Texas 78229, United States
  • Texas Cancer Center - Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology - Sugar Land
    Sugar Land, Texas 77479, United States
  • Texas Oncology-Tyler
    Tyler, Texas 75702, United States
  • Texas Oncology-Waco
    Waco, Texas 76712, United States
  • Texas Oncology Wichita Falls Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Highline Medical Oncology
    Burien, Washington 98166, United States
  • Puget Sound Cancer Centers
    Edmonds, Washington 98026, United States
  • Columbia Basin Hematology & Oncology
    Kennewick, Washington 99336, United States
  • Puget Sound Cancer Centers
    Seattle, Washington 98133, United States
  • Cancer Care Northwest
    Spokane, Washington 99202, United States
  • Evergreen Hematology & Oncology
    Spokane, Washington 99218, United States
  • Yakima Valley Memorial Hospital/North Star Lodge
    Yakima, Washington 98902, United States
  • Raleigh Regional Cancer Center dba Beckley Oncology Associates Inc.
    Beckley, West Virginia 25801, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2010
First posted
Feb 24, 2010
Start
Jan 2010
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Dec 7, 2016
Last update
Dec 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01075100
Responsible party
Sponsor
First posted
Feb 24, 2010
Start date
Jan 2010
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Dec 7, 2016
Last update
Dec 7, 2016

Study contacts

Cynthia R Osborne, MD
principal investigator · US Oncology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Carboplatin

Start the discussion